AKT1 and neoplasm: The folate-targeted PIK-75 nanosuspension not only increased drug accumulation in tumor tissues, but also improved its bioavailability, enhanced cytotoxicity, and effectively downregulated pAkt expression in the PI3K/AKT signaling pathway [63].